Company intelligence / Profile preview
PlusVitech
Seville, Andalusia, Spainplusvitech.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase 2 clinical trial with PVT-1 (repurposed aprepitant) in 24 patients with non-small cell lung cancer (NSCLC) who are refractory to standard treatment. Previous first-time-in-human studies were positive, and there is clinical evidence of complete remission in different types of cancer.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules (repurposed drugs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nanoform Finland Plc (announced April 9, 2024)
Beyond the preview
Go deeper on PlusVitech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PlusVitech.